An Eli Lilly-sponsored indirect treatment comparison links tirzepatide 10 and 15 mg to greater weight, BMI and HbA1c reductions than semaglutide 2.4 mg in patients with type 2 diabetes, with no head-to-head trial. PICO summary and expert commentary.
A phase 2b trial finds oral danuglipron produces significant weight loss in obesity but with high discontinuation from gastrointestinal side effects. PICO summary and commentary.
In adults with type 2 diabetes on basal insulin, once-weekly IcoSema was non-inferior to basal-bolus therapy for HbA1c and superior for weight, insulin dose, and hypoglycaemia. PICO summary and expert commentary.
The phase 3a COMBINE 1 trial finds once-weekly IcoSema lowers HbA1c more than insulin icodec alone while cutting hypoglycemia. PICO summary and expert commentary.
An exploratory analysis of two Phase 2 trials found that oral orforglipron produced placebo-adjusted reductions in cardiovascular risk biomarkers, not clinical events, in adults with type 2 diabetes or obesity. PICO summary and expert commentary.
A large RCT finds peri-operative exenatide does not reduce death or organ failure after CABG or aortic valve replacement. PICO summary and expert commentary.
A phase 3 open-label trial in 440 Chinese adults found the dulaglutide biosimilar LY05008 equivalent to reference dulaglutide (Trulicity) for HbA1c reduction at 24 weeks. PICO summary and expert commentary.
A phase 1 mechanistic study in adults with obesity found tirzepatide did not alter metabolic adaptation but increased fat oxidation and reduced calorie intake versus placebo. PICO summary and expert commentary.
A phase 2a crossover trial finds the GPR119 agonist MBX-2982 does not improve glucagon counterregulation in type 1 diabetes, despite target engagement. PICO summary and commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
